Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : Peking University First Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirolimus Monotherapy in the Treatment of Antiphospholipid Antibody Related Thrombocytopenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Sirolimus
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : Peking University First Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Nephrology
Study Phase : Phase II/ Phase III
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 19, 2021
Lead Product(s) : Sirolimus
Therapeutic Area : Nephrology
Highest Development Status : Phase II/ Phase III
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sirolimus
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Sirolimus for Plastic Bronchitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
May 08, 2019
Lead Product(s) : Sirolimus
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Recipient : Peking Union Medical College Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety Study of Shenwu Capsule
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
October 14, 2011